Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.65 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561598 | 0.86 | ELANE (0.67) | ELANEHTR2ANOTUMATMHTR2C | |
| SCHEMBL560968 | 0.83 | ELANE (0.63) | ELANEHTR2ANOTUMATMHTR2C | |
| SCHEMBL17378375 | 0.83 | ELANE (0.63) | ELANEHTR2ANOTUMATMHTR2C | |
| SCHEMBL18880052 | 0.82 | ELANE (0.62) | ELANEHTR2ANOTUMATMHTR2C | |
| SCHEMBL561113 | 0.82 | ELANE (0.67) | ELANEHTR2AHTR2CKCNH2CCR1 | |
| SCHEMBL31490428 | 0.82 | ELANE (0.67) | ELANEHTR2AHTR2CKCNH2CCR1 | |
| SCHEMBL17023287 | 0.82 | ELANE (0.65) | ELANECCR1 | |
| SCHEMBL17023275 | 0.82 | ELANE (0.73) | ELANECCR1 | |
| SCHEMBL31490080 | 0.82 | ELANE (0.68) | ELANEHTR2ANOTUMHTR2CKCNH2 | |
| SCHEMBL561159 | 0.82 | ELANE (0.68) | ELANEHTR2ANOTUMHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885HTR2A 2929/4885NOTUM 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.